评估布罗达卢马布用于治疗原发性硬化性胆道炎 (SABR-PSC试点研究):为单臂,多中心试点研究的协议
Amera Elzubeir1,2, Juliet High3, Matthew Hammond3
1University of East Anglia Norwich Medical School, Norwich, UK a.elzubeir@uea.ac.uk.
BMJ open gastroenterology
|March 3, 2025
概括
这项试点研究调查了 brodalumab.
科学领域:
- 肝病学和免疫学 肝病学和免疫学
- 胃肠病学 胃肠病学
- 临床试验 临床试验
背景情况:
- 初级硬化性胆道炎 (PSC) 是一种罕见的,免疫媒介性肝病,没有经批准的治疗方法.
- 介素-17 (IL-17) 途径与PSC病变发生有关.
- 准IL-17通路代表了PSC的潜在治疗策略.
研究的目的:
- 评估布罗达卢马布的安全性和可行性,一种IL-17受体A抑制剂,在患PSC的成年人中.
- 评估布罗达卢马布在改善PSC患者肝纤维化,生物化学和生活质量的疗效.
主要方法:
- 一个2a阶段,开放标签,多中心试点研究,涉及20名早期非肝硬化PSC的成年人.
- 参与者接受了布罗达卢马布,安全性和可行性是主要结果.
- 二级结局包括非侵入性纤维化评估,肝功能测试,MR胆血管学和生活质量调查问卷.
主要成果:
- 该研究目前正在招募患者,尚未报告主要或次要结果.
- 在整个研究期间,将收集安全性和可行性数据.
- 通过各种生化和成像标志物来评估有效性.
结论:
- 这项研究将为PSC中的布罗达卢马布提供关键的安全性和可行性数据.
- 结果将为未来更大的临床试验的设计提供信息,用于PSC中的IL-17途径抑制.
- 这些发现将有助于了解针对免疫媒介性肝病中的IL-17的治疗潜力.
相关概念视频
Chronic Bowel Disorders: Introduction
376
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
376
Chronic Pancreatitis II: Collaborative Care
56
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
56
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107


